What is the financial impact of the Preventice acquisition?

The acquisition of Preventice involves an upfront cash payment of $925 million and a potential additional payment of up to $300 million contingent on achieving commercial milestones. This represents a significant investment to bolster Boston Scientific's cardiac monitoring capabilities.

What is the strategic rationale behind selling the BTG Specialty Pharmaceuticals Business?

The sale of the BTG Specialty Pharmaceuticals business allows Boston Scientific to divest a segment acquired as part of the larger BTG plc acquisition in 2019. This move enables the company to focus resources and strategic efforts on its core medical device businesses, particularly in areas like cardiac rhythm management where the Preventice acquisition strengthens its position.

How does the Preventice acquisition align with Boston Scientific's existing business?

The Preventice acquisition is highly complementary to Boston Scientific's existing cardiology and cardiac rhythm management portfolio. Preventice offers a broad suite of mobile cardiac health solutions, including Holter monitors and cardiac event monitors, which will expand Boston Scientific's offerings and competitive position in the diagnostic and monitoring space.

What were the total cash considerations for these transactions?

Boston Scientific paid $925 million upfront for Preventice (with potential for an additional $300 million) and received $800 million in cash for the divestiture of the BTG Specialty Pharmaceuticals Business. The net cash outflow related to these specific transactions, considering only upfront payments, would be $125 million.

BSX 8-K SEC Disclosure

Summary

Boston Scientific Corporation (BSX) has announced the completion of two significant strategic transactions on March 1, 2021. First, the company finalized its acquisition of Preventice Solutions, Inc., a leader in mobile cardiac health solutions. This acquisition involved an upfront cash payment of $925 million, with an additional potential of $300 million tied to commercial milestones. This move aims to strengthen Boston Scientific's cardiac rhythm management portfolio by integrating Preventice's comprehensive range of cardiac monitoring devices and services. In parallel, Boston Scientific completed the divestiture of its BTG Specialty Pharmaceuticals business for $800 million in cash. This sale, to affiliates of SERB, marks a strategic step to streamline its business operations and focus on core areas following its acquisition of BTG plc in 2019. These dual transactions indicate a strategic shift, focusing on growth in medical devices while exiting a non-core pharmaceutical segment.

Key Highlights

1Boston Scientific completed the acquisition of Preventice Solutions, Inc. for an upfront payment of $925 million plus up to $300 million in potential milestones.
2The Preventice acquisition significantly enhances Boston Scientific's presence in the mobile cardiac health and monitoring solutions market.
3The company also completed the sale of its BTG Specialty Pharmaceuticals Business for $800 million in cash.
4The divestiture of the specialty pharmaceuticals business represents a strategic focus on core medical device segments.
5The transaction details were announced previously on January 21, 2021 (acquisition) and December 1, 2020 (divestiture).
6These transactions indicate a strategic realignment of Boston Scientific's business portfolio.

BOSTON SCIENTIFIC CORP 8-K Report, Corporate Update (Mar 1, 2021)

Summary

Key Highlights

Frequently Asked Questions